Intrathecal delivery of a bicistronic AAV9 vector expressing β-hexosaminidase A corrects Sandhoff disease in a murine model: A dosage study

• Published in: Molecular therapy. Methods & clinical development 2024-03, Vol.32 (1), p.101168-101168, Article 101168
• Main Authors: Ryckman, Alex E., Deschenes, Natalie M., Quinville, Brianna M., Osmon, Karlaina J.L., Mitchell, Melissa, Chen, Zhilin, Gray, Steven J., Walia, Jagdeep S.
• Format: Article
• Language: English
• Subjects: AAV; dosage; gene therapy; GM2 gangliosidosis; hexosaminidase A; Original; Sandhoff; Tay-Sachs; viral vector
• ISSN: 2329-0501; 2329-0501
• DOI: 10.1016/j.omtm.2023.101168

The pathological accumulation of GM2 ganglioside associated with Tay-Sachs disease (TSD) and Sandhoff disease (SD) occurs in individuals who possess mutant forms of the heterodimer β-hexosaminidase A (Hex A) because of mutation of the HEXA and HEXB genes, respectively. With a lack of approved therapies, patients experience rapid neurological decline resulting in early death. A novel bicistronic vector carrying both HEXA and HEXB previously demonstrated promising results in mouse models of SD following neonatal intravenous administration, including significant reduction in GM2 accumulation, increased levels of Hex A, and a 2-fold extension of survival. The aim of the present study was to identify an optimal dose of the bicistronic vector in 6-week-old SD mice by an intrathecal route of administration along with transient immunosuppression, to inform possible clinical translation. Three doses of the bicistronic vector were tested: 2.5e11, 1.25e11, and 0.625e11 vector genomes per mouse. The highest dose provided the greatest increase in biochemical and behavioral parameters, such that treated mice lived to a median age of 56 weeks (>3 times the lifespan of the SD controls). These results have direct implications in deciding a human equivalent dose for TSD/SD and have informed the approval of a clinical trial application (NCT04798235). [Display omitted] In this study, Ryckman and colleagues not only confirmed the therapeutic promise of a novel bicistronic adeno-associated vector serotype 9 for GM2 gangliosidosis patients but also demonstrated its dose-responsive behavior in mice via single intrathecal lumbar puncture delivery.